ALVIO — Valerio Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €195.03m
- €201.58m
- €2.57m
Brief: Onxeo Presents Positive AsiDNA Preclinical Study Results
Brief: Onxeo Says To Record Impairment Charge
Brief: Onxeo Provides Update on Litigation with SpeBio/SpePharm
Brief: Onxeo reports commercial court of Paris decision in lawsuit against SpeBio/SpePharm
Brief: Onxeo introduces chemistry platform of decoy oligonucleotides platON
Brief: Onxeo announces preclinical data for combination of AsiDNA and belinostat
Brief: Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics
Brief: Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma
Brief: Onxeo divests two non-core products to Vectans Pharma
Brief: Onxeo H1 net loss stable at 11.6 million euros
Brief: Onxeo announces positive preclinical proof of concept results for AsiDNA
Brief: Onxeo launches capital increase by means of accelerated book-build offering
Brief: Onxeo announces allowance of U.S. patent for Livatag in hepatocellular carcinoma
Brief: Onxeo Q1 revenue up 55 pct to 1.2 million euros
Brief: Clinigen and Onxeo initiate managed access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)
Brief: Onxeo to present data at AACR annual meeting
Brief: Onxeo FY net loss widens to 22.7 million euros
Brief: Onxeo announces chief medical and scientific officers
Brief: Onxeo receives USPTO Notice Of Allowance for a new AsiDNATM-related patent